Nonalcoholic fatty liver disease: New drug proves ‘safe’ and effective

A double-blind, placebo-controlled randomized clinical trial finds the right dosage at which a drug ‘safely’ treats nonalcoholic fatty liver disease. %hepatitis C treatment%